

## ***Gut microbiota and well-being***

### **Publications**

#### **2009**

Appeldoorn M.M, Vincken J.-P, Aura A.-M, Hollman P.C.H. & Gruppen, H. 2009. Procyanidin dimers are metabolized by human microbiota with 2-(3,4-dihydroxyphenyl)acetic acid and 5-(3,4-dihydroxyphenyl)- $\gamma$ -valerolactone as the major metabolites. *J. Agric. Food Chem.* 57, 1084-1092.

Bondia-Pons I, Aura A.-M, Vuorela S, Kolehmainen M, Mykkänen H. & Poutanen, K. 2009. Rye phenolics in nutrition and health. *J. Cereal Sci.* In press.

Lahtinen S.J, Tammela L, Korpela J, Parhiala R, Ahokoski H, Mykkänen H & Salminen S.J. Probiotics modulate the *Bifidobacterium* microbiota of elderly nursing home residents. *AGE* 31, 59-66, 2009.

#### **2008**

Aura A.-M, Mattila, I, Seppänen-Laakso T, Miettinen J, Oksman-Caldentey K.-M. & Oresic, M. 2008. Microbial metabolism of catechin stereoisomers by human faecal microbiota: Comparison of targeted analysis and a non-targeted metabolomics method. *Phytochem. Lett.* 1, 18-22.

Bazzocco S, Mattila I, Guyot S, Renard C.M.G.C. & Aura A.-M. 2008. Factors affecting the conversion of apple polyphenols to phenolic acids and fruit matrix to short-chain fatty acids by human faecal microbiota *in vitro*. *Eur. J. Nutr.* 47, 442-452.

Maukonen J, Mättö J, Kajander K, Mattila-Sandholm T & Saarela M. Diversity and temporal stability of fecal bacterial populations in elderly subjects consuming galacto-oligosaccharide containing probiotic yoghurt. *Int. Dairy J* 2008: 18: 386-395.

Maukonen J, Mättö J, Suihko M-L & Saarela M. Intraindividual diversity and similarity of salivary and fecal microbiota. *J Med Microbiol* 2008: 57: 1560-1568.

Mättö J, Maukonen J, Alakomi H-L, Suihko M-L & Saarela M. Influence of oral doxycycline therapy on the diversity and antibiotic susceptibility of human intestinal bifidobacterial population. *J Appl Microbiol* 2008: 105: 279–289.

#### **2007**

Alakomi H.-L, Puupponen-Pimiä R, Aura A.-M, Helander I.M, Nohynek L, Oksman-Caldentey K.-M. & Saarela, M. 2007. Weakening of *Salmonella* with selected microbial metabolites of berry-derived phenolic compounds and organic acids. *J. Agric. Food Chem.* 55, 3905-3912.

Aura A.-M, Myllymäki O, Bailey M, Penalvo J.-L, Adlercreutz H. & Poutanen K. 2007. Interrelationships between carbohydrate type, phenolic acids and initial pH on *in vitro* conversion of enterolactone from rye lignans. *In: Dietary Fibre Components and Functions.* Salovaara, H., Gates, F. & Tenkanen, M. (eds). Wageningen Academic Publishers, The Netherlands, 235-245.

Nyström L, Lampi A.-M, Rita H, Aura A.-M, Oksman-Caldentey K.-M. & Piironen V. 2007. Effects of processing on availability of total plant sterols, steryl ferulates and steryl glycosides from wheat and rye bran. *J. Agric. Food Chem.* 55, 9059-9065.

Saarela M, Maukonen J, von Wright A, Vilpponen-Salmela T, Patterson AJ, Scott KP, Hämynen H & Mättö J. Tetracycline susceptibility of the ingested *Lactobacillus acidophilus* LaCH-5 and *Bifidobacterium animalis* subsp. *lactis* Bb-12 strains during antibiotic-probiotic intervention Int J Antimicrob Agents 2007: 29: 271-280.

Sairanen U, Piirainen L, Gråsten S, Tompuri T, Mättö J, Saarela M & Korpela R. The effect of probiotic fermented milk and inulin on the functions and microecology of the intestine. J Dairy Res 2007: 74: 367-373.

## 2006

Aura A.-M, Oikarinen S, Mutanen M, Heinonen S.-M, Adlercreutz H, Virtanen H. & Poutanen K. 2006. Suitability of a batch *in vitro* fermentation model using human faecal microbiota for prediction of conversion of flaxseed lignans to enterolactone with reference to an *in vivo* rat model. Eur. J. Nutr. 45, 45-51.

Gonthier M.-P, Remesy C, Scalbert A, Cheynier V, Souquet J.-M, Poutanen K. & Aura A.-M. 2006. Microbial metabolism of caffeic acid and its esters chlorogenic and caftaric acids by human faecal microbiota *in vitro*. Biomed. Pharmacother. 60, 536-540.

Maukonen J, Satokari R, Mättö J, Söderlund H, Mattila-Sandholm T & Saarela M. Prevalence and temporal stability of selected clostridial groups in irritable bowel syndrome in relation to predominant fecal bacteria. J Med Microbiol 2006: 55: 625-633.

Maukonen J, Mättö J, Satokari R, Söderlund H, Mattila-Sandholm T & Saarela M. PCR-DGGE and RT-PCR-DGGE show diversity and short-term temporal stability in *Clostridium coccoides* – *Eubacterium rectale* group of clostridia in human intestinal microbiota. FEMS Microbiol Ecol 2006: 58: 517-528.

Maukonen J, Alakomi H-L, Nohynek L, Hallamaa K, Leppämäki S, Mättö J & Saarela M. Suitability of the fluorescent techniques for the enumeration of probiotic bacteria in commercial non-dairy drinks and in pharmaceutical products. Food Res Int 2006: 39: 22-32.

Mättö J, Fonden R, Mikkola T, von Wright A, Vilpponen-Salmela T, Satokari R, Saarela M. Intestinal survival and persistence of probiotic *Lactobacillus* and *Bifidobacterium* strains administered in triple-strain yoghurt. Int Dairy J 2006: 16: 1174-1180.

Suomalainen T, Lagström H, Mättö J, Saarela M, Arvilommi H, Laitinen I, Ouwehand AC, Salminen S. Influence of whey-based fruit juice containing *Lactobacillus rhamnosus* on intestinal well-being and humoral immune response in healthy adults. LWT Food Sci Technol 2006: 39: 788-795.

Söderling E, Karjalainen S, Lille M, Maukonen J, Saarela M & Autio K (2006). The effect of liquorice extract-containing starch gel on the amount and microbial composition of plaque. Clin Oral Invest 2006: 10: 108-113.

## 2005

Aura A.-M, Karppinen S, Virtanen H, Forssell P, Heinonen S.-M, Nurmi T, Adlercreutz H. & Poutanen K. 2005. Processing of rye bran influences both the fermentation of dietary fibre and the bioconversion of lignans by human faecal flora *in vitro*. J. Sci. Food Agric. 85, 2085-2093.

Aura A.-M, Martin-Lopez P, O'Leary K.A, Williamson G, Oksman-Caldentey K.-M, Poutanen K. & Santos-Buelga C. 2005. *In vitro* metabolism of anthocyanins by human gut microflora. Eur. J. Nutr. 44, 133-142.

Peñalvo J.L, Heinonen S.-M, Aura A.-M. & Adlercreutz H. 2005. Dietary sesamin is converted to enterolactone in humans. *J. Nutr.* 135, 1056-1062.

Malinen E, Rinttilä T, Kajander K, Mättö J, Kassinen A, Krogius L, Saarela M, Korpela R, Palva A. Analysis of the fecal microbiota of irritable bowel syndrome patients and healthy controls with real-time PCR. *Am J Gastroenterol* 2005: 100: 373-382.

Mättö J, Maunuksela L, Kajander K, Palva A, Korpela R, Kassinen A, Saarela M. Composition and temporal stability of gastrointestinal microbiota in irritable bowel syndrome – a longitudinal study in IBS and control subjects. *FEMS Immunol Med Microbiol* 2005: 43: 213-222.

## 2004

Heinonen S.-M, Wähälä K, Liukkonen K.-H, Aura A.-M, Poutanen K. & Adlercreutz H. 2004. Studies of the *in vitro* intestinal metabolism of isoflavones aid in the identification of their urinary metabolites. *J. Agric. Food Chem.* 52, 2640-2646.

Mättö J, Malinen E, Suihko M-L, Alander M, Palva A, Saarela M. Genetic heterogeneity and functional properties of intestinal bifidobacteria. *J Appl Microbiol* 2004: 97: 459-470.

## 2003

Oikarinen S, Heinonen S, Karppinen S, Mättö J, Adlercreutz H, Poutanen K, Mutanen M. Plasma enterolactone or caecal *Bifidobacterium* levels do not explain adenoma formation in multiple neoplasia (Min) mice fed with two different types of rye fractions. *Br J Nutr* 2003: 90: 119-125.

## 2002

Aura A.-M, O'Leary K.A, Williamson G, Ojala M, Bailey M, Puupponen-Pimiä R, Nuutila A.M, Oksman-Caldentey K.-M. & Poutanen K. 2002. Quercetin derivatives are deconjugated and converted to hydroxyphenylacetic acids but not methylated by human fecal flora *in vitro*. *J. Agric. Food Chem.* 50, 1725-1730.

Crittenden R, Karppinen S, Ojanen S, Tenkanen M, Fagerström R, Mättö J, Saarela M, Mattila-Sandholm T, Poutanen K. *In vitro* fermentation of cereal dietary fibre carbohydrates by probiotic and intestinal bacteria. *J Sci Food Agric* 2002: 82: 781-789.

Malinen E, Mättö J, Salmitie M, Alander M, Saarela M, Palva A. PCR-ELISA II: Analysis of *Bifidobacterium* populations in human faecal samples from a consumption trial with *Bifidobacterium lactis* Bb-12 and a galacto-oligosaccharide preparation. *System Appl Microbiol* 2002: 25: 249-258.

Kontula P, Nollet L, Saarela M, Vilpponen-Salmela T, Verstraete W, Mattila-Sandholm T, von Wright A. The effect of lactulose on the survival of *Lactobacillus rhamnosus* in the Simulator of the Human Intestinal Microbial Ecosystem (SHIME) and *in vivo*. *Microbial Ecol Health Dis* 2002: 14: 90-96.

## 2001

Alander M, Mättö J, Kneifel W, Johansson M, Kögler B, Crittenden R, Mattila-Sandholm T, Saarela M. Effect of galacto-oligosaccharide supplementation on human faecal microflora and on survival and persistence of *Bifidobacterium lactis* Bb-12 in the gastrointestinal tract. *Int Dairy J* 2001: 11: 817-825.

Harmoinen J.A, Mättö J.M, Rinkinen M.L, Wilsson-Rahmberg M, Westermarck E. Permanent jejunal fistula: promising method for obtaining small intestinal chyme without disturbing intestinal function. *Comp Med* 2001: 51: 252-6.

Satokari R, Vaughan E, Akkermans A, Saarela M, de Vos W. Bifidobacterial diversity in human feces detected by genus-specific polymerase chain reaction and denaturing gradient gel electrophoresis. *Appl Environ Microbiol* 2001; 67: 504-513.

Satokari R, Vaughan E, Akkermans A, Saarela M, de Vos W. Polymerase chain reaction and denaturing gradient gel electrophoresis monitoring of fecal bifidobacterial populations in a prebiotic and probiotic feeding trial. *System Appl Microbiol* 2001; 24: 227-231.

## 2000

Hannula J, Saarela M, Dogan B, Paatsama J, Koukila-Kähkölä P, Pirinen S, Alakomi H-L, Perheentupa J, Asikainen S. Comparison of virulence factors of oral *Candida dubliniensis* and *Candida albicans* isolates in healthy persons and patients with chronic candidosis. *Oral Microbiol Immunol* 2000; 15: 238-244.

Karppinen S, Liukkonen K, Aura A.-M, Forssell P. & Poutanen K. 2000. *In vitro* fermentation of polysaccharides of rye, wheat and oat brans and inulin by human faecal bacteria. *J. Sci. Food Agric.* 80, 1469-1476.

Könönen E, Wolf J, Mättö J, Frandsen EVG, Poulsen K, Jousimies-Somer H, Asikainen S. The *Prevotella intermedia* group organisms in young children and their mothers as related to maternal periodontal status. *J Periodont Res* 2000; 35: 329-334.

Paju S, Saarela M, Chen C, Jousimies-Somer H, Uitto V-J, Asikainen S. Altered antigenicity is seen in the lipopolysaccharide profile of non-serotypeable *Actinobacillus actinomycetemcomitans* strains. *FEMS Immunol Med Microbiol* 2000; 27: 171-177.

## 1999

Aura A.-M, Härkönen H, Fabritius M. & Poutanen K. 1999. Development of an *in vitro* enzymic digestion method for removal of starch and protein and assessment of its performance using rye and wheat breads. *J. Cereal Sci.* 29, 139-152.

Dogan B, Saarela M, Jousimies-Somer H, Alaluusua S, Asikainen S. *Actinobacillus actinomycetemcomitans* serotype e - biotypes, genetic diversity and distribution in relation to periodontal status. *Oral microbiol Immunol* 1999; 14: 98-103.

Hannula J, Saarela M, Jousimies-Somer H, Takala A, Syrjänen R, Asikainen S. Age-related acquisition of oral and nasopharyngeal yeast species and stability of colonization in young children. *Oral Microbiol Immunol* 1999; 14: 176-182.

Mättö J, Asikainen S, Väisänen M-L, von Troil-Linden B, Könönen E, Saarela M, Salminen K, Finegold S, Jousimies-Somer H. B-lactamase production in *Prevotella intermedia*, *Prevotella nigrescens*, and *Prevotella pallens* genotypes and *in vitro* susceptibilities to selected antimicrobial agents. *Antimicrobial Agents Chemother* 1999; 43: 2383-2388.

Saarela M, Dogan B, Alaluusua S, Asikainen S. Persistence of oral colonization by the same *Actinobacillus actinomycetemcomitans* strain(s). *J Periodontol* 1999; 5: 504-509.

## 1998

Aura A.M, von Wright A, Alander M, Fabritius M, Suortti T. & Poutanen, K. 1998. *In vitro* fermentation of enzymatically digested rye bread: preparation of the fecal inoculum. *In: Functional*

Foods. The Consumer, the Products and the Evidence. Sadler, M.J. & Saltmarsh, M. (eds). The Royal Society of Chemistry, Cambridge, UK, 55-58.

Grönroos L, Saarela M, Mättö J, Tanner-Salo U, Vuorela A, Alaluusua S. Mutacin production by *Streptococcus mutans* may promote transmission from mother to child. *Infect Immun* 1998; 66: 2595-2600.

Mättö J, Saarela M, Alaluusua S, Oja V, Jousimies-Somer H, Asikainen S. Detection of *Porphyromonas gingivalis* from saliva by PCR using simple sample processing. *J Clin Microbiol* 1998; 36: 157-160.

Poutanen K, Suortti T, Aura A.-M, Liukkonen K. & Autio K. 1998. Influence of processing on cereal dietary fibre complex: what do we know now? *In: Functional Properties of Non-Digestible Carbohydrates*. Guillon, F., Amado, R., Amaral-Collaco, M.T., Andersson, H., Asp, N.G., Bach Knudsen, K.E., Champ, M., Mathers, J., Robertson, J.A., Rowland, I. & Van Loo, J. (eds). INRA, Nantes, 66-70.

## 1997

Alaluusua S, Grönroos L, Zhu X, Saarela M, Mättö J, Asikainen S, Fukushima K. Production of glucosyltransferases by clinical mutans streptococcal isolates as determined by semi-quantitative cross-dot assay. *Archs Oral Biol* 1997; 42: 417-422.

Asikainen S, Chen C, Saarela M, Saxen L, Slots J. Clonal specificity of *Actinobacillus actinomycetemcomitans* in destructive periodontal disease. *Clin Infect Dis* 1997; 25(Suppl 2):S227-S229.

Hannula J, Saarela M, Alaluusua S, Slots J, Asikainen S. Phenotypic and genotypic characterization of oral yeast from Finland and the United States. *Oral Microbiol Immunol* 1997; 12: 358-365.

Könönen E, Nyfors S, Mättö J, Asikainen S, Jousimies-Somer H. -lactamase production by oral pigmented *Prevotella* species isolated from young children. *Clin Infect Dis* 1997; 25 (Suppl 2): S272-S274.

Mättö J, Asikainen S, Väisänen M-L, Rautio M, Saarela M, Summanen P, Finegold S, Jousimies-Somer H. Role of *Porphyromonas gingivalis*, *Prevotella intermedia*, and *Prevotella nigrescens* in extraoral and some odontogenic infections. *Clin Infect Dis* 1997; 25 (Suppl 2): S194-S198.

Willi K, Sandmeier H, Asikainen S, Saarela M, Meyer J. Occurrence of temperate bacteriophages in different *Actinobacillus actinomycetemcomitans* serotypes isolated from periodontally healthy individuals. *Oral Microbiol Immunol* 1997; 12: 40-46.

## 1996

Alaluusua S, Mättö J, Grönroos L, Innilä S, Torkko H, Asikainen S, Jousimies-Somer H, Saarela M. Oral colonization by more than one clonal type of mutans streptococcus in children with nursing bottle caries. *Archs Oral Biol* 1996; 41: 167-173.

Mättö J, Saarela M, von Troil-Lindén B, Könönen E, Jousimies-Somer H, Torkko H, Alaluusua S, Asikainen S. Distribution and genetic analysis of oral *Prevotella intermedia* and *Prevotella nigrescens*. *Oral Microbiol Immunol* 1996; 11: 96-102.

Mättö J, Saarela M, von Troil-Lindén B, Alaluusua S, Jousimies-Somer H, Asikainen S. Similarity of salivary and subgingival *Prevotella intermedia* isolates by arbitrarily primed polymerase chain reaction. *Oral Microbiol Immunol* 1996: **11**: 395-401.

Saarela M, Mättö J, Asikainen S, Jousimies-Somer H, Torkko H, Pyhälä L, Stucki A-M, Hannula J, Hölttä P, Alaluusua S. Clonal diversity of *Actinobacillus actinomycetemcomitans*, *Porphyromonas gingivalis* and *Prevotella intermedia/nigrescens* in two families. *Anaerobe* 1996: **2**: 19-27.

Saarela M, Hannula J, Mättö J, Asikainen S, Alaluusua S. Typing of mutans streptococci by arbitrarily primed polymerase chain reaction. *Archs Oral Biol* 1996: **41**: 821-826.

von Troil-Lindén B, Saarela M, Mättö J, Alaluusua S, Jousimies-Somer H, Asikainen S. Source of suspected periodontal pathogens re-emerging after periodontal treatment. *J Clin Periodontol* 1996: **23**: 601-607.

### **1995**

Grönroos L, Mättö J, Saarela M, Luoma A-R, Luoma H, Jousimies-Somer H, Pyhälä L, Asikainen S, Alaluusua S. Chlorhexidine susceptibilities of mutans streptococcal serotypes and ribotypes. *Antimicrobial Agents Chemother* 1995: **39**: 894-898.

Könönen E, Saarela M, Kanervo A, Karjalainen J, Asikainen S, Jousimies-Somer H.  $\beta$ -lactamase production and penicillin susceptibility among different ribotypes of *Prevotella melaninogenica* simultaneously colonizing the oral cavity. *Clin Infect Dis* 1995: **20** (suppl 2): S364-S366.

### **1994**

Alaluusua S, Alaluusua SJ, Karjalainen J, Saarela M, Holttinen T, Kallio M, Hölttä P, Torkko H, Relander P, Asikainen S. The demonstration by ribotyping of the stability of *Streptococcus mutans* infection over 5 to 7 years in children. *Archs Oral Biol* 1994: **39**: 467-471.

Hölttä P, Alaluusua S, Saarela M, Asikainen S. Isolation frequency and serotype distribution of mutans streptococci and *Actinobacillus actinomycetemcomitans*, and clinical periodontal status in a group of Finnish and Vietnamese children. *Scan J Dent Res* 1994: **102**: 113-119.

Könönen E, Asikainen S, Saarela M, Karjalainen J, Jousimies-Somer H. The oral gram-negative anaerobic microflora in young children: longitudinal changes from edentulous to dentate mouth. *Oral Microbiol Immunol* 1994: **9**: 136-141.

Könönen E, Saarela M, Karjalainen J, Jousimies-Somer H, Alaluusua S, Asikainen S. Transmission of oral *Prevotella melaninogenica* between a mother and her young child. *Oral Microbiol Immunol* 1994: **9**: 310-314.

### **1993**

Alaluusua S, Saarela M, Jousimies-Somer H, Asikainen S. Ribotyping shows intrafamilial similarity in *Actinobacillus actinomycetemcomitans* strains. *Oral Microbiol Immunol* 1993: **8**: 225-229.

Saarela M, Stucki A-M, von Troil-Lindén B, Alaluusua S, Jousimies-Somer H, Asikainen S. Intra- and interindividual comparison of *Porphyromonas gingivalis* genotypes. *FEMS Immunol Med Microbiol* 1993: **6**: 99-102.

Saarela M, Alaluusua S, Takei T, Asikainen S. Genetic diversity within isolates of mutans streptococci recognized by an rRNA gene probe. *J Clin Microbiol* 1993: **31**: 584-587.

Saarela M, von Troil-Lindén B, Torkko H, Stucki A-M, Alaluusua S, Jousimies-Somer H, Asikainen S. Transmission of oral bacterial species between spouses. *Oral Microbiol Immunol* 1993; 8: 349-354.

### Peer reviewed reviews

Aura A.-M. 2008. Microbial metabolism of dietary phenolic compounds in the colon. *Phytochem. Rev.* 7, 407-429.

Mattila-Sandholm T, Mättö J, Saarela M. Lactic acid bacteria with health claims - interactions and interference with gastrointestinal flora. *Int Dairy J* 1999; 9: 25-35.

Puupponen-Pimiä R, Aura A.-M, Karppinen S, Oksman-Caldentey K.-M. & Poutanen K. 2004. Interactions between plant bioactive food ingredients and intestinal flora - effects on human health. *Bioscience Microflora* 23, 67-80.

Puupponen-Pimiä R, Aura A.-M, Oksman-Caldentey K.-M, Myllärinen P, Saarela M, Mattila-Sandholm T. & Poutanen K. 2002. Development of functional ingredients for gut health. *Trends Food Sci. Technol.* 13, 3-11.

Saarela M, Lähteenmäki L, Crittenden R, Salminen S, Mattila-Sandholm T. Gut bacteria and health foods - the European perspective. *Int J Food Microbiol*, 2002: 78: 99-117.

Satokari R, Vaughan EE, Smidt H, Saarela M, Mättö J, De Vos WM. Molecular approaches for the detection and identification of bifidobacteria and lactobacilli in the human gastrointestinal tract. *System Appl Microbiol*, 2003: 26: 572-584.

### Other reviews & chapters in books

Karppinen S, Liukkonen K, Aura A.-M. Forssell P. & Poutanen K. 2000. Wheat and rye brans: what is the difference? *In: Functional Foods II.* Buttriss, J. & Saltmarsh, M. (eds). Royal Society of Chemistry, London, 200-202.

Mattila-Sandholm T, Blaut M, Daly C, de Vuyst L, Dore J, Gibson G, Goossens H, Knorr D, Lucas J, Lähteenmäki, L, Mercenier A, Saarela M, Shanahan F, de Vos WM. Food, GI-tract functionality and human health cluster: PROEUHEALTH. *Microbial Ecol Health Dis* 2002: 14: 65-74.

Mattila-Sandholm T, Saarela M, de Vos W. The food, GI-tract functionality and human health cluster: PROEUHEALTH and beyond. *Microb Ecol Health Dis* 2004: 16: 66-70.

Mattila-Sandholm T, Lähteenmäki L, Saarela M. EU Perspectives on Food, Gastrointestinal Tract Functionality, and Human Health. *In: I Goktepe, VK Juneja, M Ahmedna (Eds) Probiotics in Food Safety and Human Health*, CRC Press, Taylor & Francis, Boca Raton, FL, ISBN: 1574445146, 2006, pp.309-339.

Puupponen-Pimiä R, Aura A.-M, Oksman-Caldentey K.-M, Myllärinen P, Saarela M, Mattila-Sandholm T, Poutanen K. Development of functional ingredients for gut health. *Trends Food Sci Technol* 2002: 13: 3-11.

### Trade journals

Asikainen S, Jousimies-Somer H, Saarela M, Alaluusua S. Sairaajan ja terveen parodontiumin *Actinobacillus actinomycescomitans* -löydös. *Suomen Hammaslääkärilehti* 1992: 16: 1115-1117. (in Finnish).

Asikainen S, Chen C, von Troil-Lindén B, Saarela M, Mättö J, Nowzari H, Slots J. La parodontite est-elle transmissible entre époux? Journal de parodontologie & d'implantologie orale. 1997; 16: 363-368. (in French)

Aura A.-M, Liukkonen K, Myllärinen P, Vesterinen E, Oksman-Caldentey K.-M. & Poutanen K. 2000. *In vitro* -ruoansulavuusmallit funktionaalisten elintarvikkeiden ja lääkeaineiden tuotekehityksen tukena. DOSIS 16(1), 53-62.

Karppinen S, Aura A.-M, Forssell P. & Poutanen K. 1998. Mahdollisuudet vaikuttaa ihmisen suolistoflooraan sulamattomien hiilihydraattien avulla. Kirjallisuuskatsaus. VTT Tiedotteita 1896. 57 s.

Mattila-Sandholm T, Saarela M, Lähteenmäki L. Gut health foods. The World of Food Ingredients. February 2004, 50-52.

Mattila-Sandholm T, Saarela M. VTT Biotechnology's activities in the guthealth area – research focusing on probiotic technology and human GI-tract microbiota. Innovation in Food technology, May 2004, 22-23.

Saarela M. Oraaliptogeneit tarttuvat perheenjäsenten välillä. Suomen Hammaslääkärilehti 1994: 1: 116-117. (in Finnish).

Saarela M. Mikrobitasapaino järkkyy ihmisten omilla toimilla. Kehittyvä Elintarvike, 2002, 1, 30-31. (in Finnish).

### **Dr Thesis**

Aura A.-M. 2005. *In vitro* digestion models for dietary phenolic compounds. VTT Biotechnology, Espoo. 107 p. + app. 57 p. VTT Publications 575. ISBN 951-38-6661-0; 951-38-6662-9.

### **Posters**

Aura A.-M, Martinez de Marañón E, Härkönen H. & Poutanen K. 1995. *In vitro* digestibility of whole meal rye flour. In: International Rye Symposium: Technology and products. Helsinki, 7-8 Dec. 1995. Poutanen, K. & Autio, K. (eds.). Espoo. VTT Symposium 161, 213.

Aura A.-M, Autio K, Härkönen H. & Poutanen K. 1996. *In vitro* digestibility of wheat and rye breads. INRA & CNRS Symp. Plant polysaccharides. Nantes, 17-19 July 1996, 75.

Aura A.-M, Härkönen H, Mårtensson A.-C, Åman P. & Poutanen K. 1997. Process effects on the digestibility of carbohydrates of rye breads. 3rd Nordfood Conf. Sustainable food production and competitive industries. Copenhagen, 23-25 Nov. 1997, 139.

Aura A.M, Ojala M, Bailey M, O'Leary K, Williamson G, Nuutila A.M, Oksman-Caldentey K.-M. & Poutanen K. 2001. Microbial *in vitro* metabolism of rutin involves deglycosylation and conversion of hydroxyphenylacetic acids. Final COST 916 Conf. Bioactive Compounds in Plant Foods. Tenerife, 26-28 Apr. 2001, 127.

Aura A.-M, Puupponen-Pimiä R, Kähkönen M, Heinonen M, Nuutila A. M. & Oksman-Caldentey K.-M. 2001. Effects of the enzymatic *in vitro* digestion on phenolic compounds present in berries. 3rd Int. Conf. Natural Antioxidants and Anticarcinogens in Food, Health and Disease (NAHD 2001). Helsinki, 6-9 June 2001, 109.

Aura A.-M, Heinonen S.-M, Karppinen S, Liukkonen K.-H, Adlercreutz H, Oksman-Caldentey K.-M. & Poutanen K. 2002. Effect of carbohydrates on mammalian lignan conversion by human faecal flora *in vitro*. Int. Symp. Dietary Phytochemicals and Human Health. Salamanca, 18-20 Apr. 2002, 109-110.

Aura A.-M, Ojala M, Bailey M, O'Leary K.A, Williamson G, uutila A.M, Oksman-Caldentey K.-M. & Poutanen K. 2002. Microbial *in vitro* metabolism of rutin involves deglycosylation and conversion of hydroxyphenylacetic acids. COST Action 916: Bioactive plant cell wall components in nutrition and health. Proc. Eur. Sci. Conf. Bioactive Compounds in Plant Foods, Tenerife, 26-28 April 2001. Amado, R. et al. (eds). Office for Official Publications of the European Communities, Luxembourg, 229-230.

Aura A.-M, Santos-Buelga C, Martín-López P, O'Leary K.A, Williamson G., Oksman-Caldentey .-M. & Poutanen K. 2002. Microbial *in vitro* deglycosylation of anthocyanins and rutin by human faecal flora. Int. Symp. Dietary Phytochemicals and Human Health. Salamanca, 18-20 Apr. 2002, 111-112.

Aura A.-M, Seppänen-Laakso T, Bounsaythip C. & Oksman-Caldentey K.-M. 2006. Prediction of microbial metabolism of phytochemicals using an *in vitro* colon model. 54th Annual Congress on Medicinal Plant Research. Helsinki, Finland, 29 Aug. - 2 Sept. 2006. Planta Medica 72 (11), 1081.GA Poster Award

Aura A.-M, Vainionpää M, Heinonen M, Martinez Lopez P, Santos-Buelga C, Oksman-Caldentey K.-M, Puupponen-Pimiä R. & Poutanen K. 2004. Anthocyanins and their metabolism in the *in vitro* gastrointestinal tract. XXII Int. Conf. Polyphenols. Helsinki, Finland, 25-28 Aug. 2004. In: Polyphenols Communications 2004. Hoikkala, A. & Soidinsalo, O. (eds). Helsinki: University of Helsinki, Organic Chemistry Laboratory, 121.

Bondia Pons I, Selinheimo E, Mattila I, Aura A.-M, Oresic M, Mykkänen H, Kolehmainen M. & Poutanen K. 2009. Application of a GCxGC-TOF platform to study the effect of the protein digestibility of rye and wheat bread on the postprandial insulin response in healthy Finnish subjects. Mass Spectrometry Metabolomics Workshop. Copenhagen, Denmark, 24-27 Feb. 2009. University of Copenhagen, 90.

Flander L, Myllärinen P. Aura A.-M. Penalvo J.-L, Adlercreutz H. & Poutanen K. 2006. Linseed press cake flour as a source of lignans in bakery products. Dietary Fibre 2006. Multifunctional Complex of Components. Helsinki, Finland, 12-14 June 2006.

Hanhineva K, Aura A.-M, Bondia-Pons I, Kolehmainen M, Mykkänen H. & Poutanen K. 2009. Non-targeted metabolite profiling of rye bran metabolome processed by human microbiota *in vitro*. C&E Spring Meeting 2009 - Whole Grain Global Summit. Newcastle upon Tyne, UK, 25-27 March 2009. AACC International. Cereal Foods World. Online Supplement. Vol. 54 (No: 2), OS24.

Heinonen S.-M, Peñalvo J.L, Nurmi T, Aura A.-M, Poutanen K, Deyama T, Nishibe S. & Adlercreutz H. 2003. *In vitro* metabolism of sesamin, a sesame seed lignan. Joint Symp. Lipid and Cereal Sciences. Vichy, France, 15-17 Nov. 2003.

Karppinen S, Liukkonen K, Aura A.-M, Suortti T, Forssell P. & Poutanen K. 1998. *In vitro* fermentation of polysaccharides in rye, wheat and oat bran. In: Functional Food Research in Europe, Mattila-Sandholm, T. & Kauppila, T. (eds). 3rd Workshop Demonstration of the nutritional functionality of probiotic foods, FAIR CT96-1028. Haikko Mano, 1-2 Oct. 1998. VTT Symposium 187, 81.

Karppinen S, Liukkonen K, Aura A.-M, Forssell P & Poutanen K. 1999. Wheat and rye brans: what is the difference? Functional Foods '99. Wye, Kent, 14-15 April 1999, 47.

Karppinen S, Aura A.-M, Heinonen S.-M, Adlercreutz, H, Forssell P. & Poutanen K. 2003. The effect of xylanase treatment of rye bran on fermentation of dietary fibre and lignan conversion *in vitro*. Dietary Fibre 2003. Noordwijkerhout, 18-21 May 2003, 108.

Mattila I, Seppänen-Laakso T. & Aura A.-M. 2006. GC/MS analysis of microbial metabolites from flavanols in an *in vitro* human colon model. 17th International Mass Spectrometry Conference. Prague, Czech Republic, Aug 27 - Sept. 1, 2006.

Mattila I, Aura A.-M. Bazzocco S, Miettinen J, Seppänen-Laakso T. & Oresic M. 2007. Analysis of human gut model metabolites by GCxGC-TOF. Plants for Human Health in the Post-Genome Era. PSE Congress. Helsinki, FI, 26-29 Aug. 2007. Kuokka-Ihalainen, A., Oksman-Caldentey, K.-M., Rischer, H. & Ritala, A. (eds). VTT Symposium 249. VTT, Espoo. 59/A1.

Myllärinen P, Forssell P. Saarela M, Aura A, Poutanen K. & Mattila-Sandholm T. 2001. Starch based control released system for probiotics. Proc. Probiotics & Prebiotics. Rome, 2-4 Sept. 2001, 235.

Myllärinen P, Forssell P, Mättö J, Laitila A, Saarela M, Vaari A, Virkajärvi I, Aura A, Poutanen K. & Mattila-Sandholm T. 2002. Starch based controlled release systems for probiotics. *In: The Food, GI-tract Functionality and Human Health Cluster. PROEUHEALTH. Saariselkä, Finland, 1-3 Feb. 2002.* Kuokka, A., Saarela, M. & Mattila-Sandholm, T. (eds). VTT Biotechnology, Espoo. VTT Symposium 219, 53.

Poutanen K, Karppinen S, Aura A.-M, Gråsten S. & Mykkänen H. 2002. Arabinoxylans and gut health. AACC Annu. Meet. Montreal, 13-17 Oct. 2002, 77.

Puupponen-Pimiä R, Nohynek L, Alakomi H.-L, Aura A.-M. & Oksman-Caldentey K.-M. 2004. Berry phenolics and their antimicrobial properties. The Satellite Symposium on Berries in Cancer Prevention: from experimental findings to humans. Lahti, Finland, 10-11 July 2004.

Maukonen J, Mättö J, Saarela M. (2004, March). Diversity of *Desulfovibrionaceae*-related and predominant bacterial populations in feces and saliva detected by group-specific and universal PCR-DGGE. The food, GI-tract functionality and human health cluster – PROEUHEALTH. 3<sup>rd</sup> Workshop. Sitges, Spain. 80.

Maukonen JM, Satokari RM, Mättö JMS, Söderlund H, Saarela MH. Temporal Stability and Abundance of Predominant and Clostridial Gastrointestinal Microbiota in Irritable Bowel Syndrome, ASM 105<sup>th</sup> general meeting, Atlanta, Georgia, USA June 6-9, 2005.

Maukonen JM, Mättö JMS, Satokari RM, Söderlund H, Mattila-Sandholm T, Saarela MH. *Clostridium coccooides* – *Eubacterium rectale* group specific DGGE shows diversity and short-term temporal stability in human intestinal microbiota. American Society for Microbiology, 106th General Meeting, Orlando, Florida, USA, May 21-25, 2006.

Maukonen J, Väänänen A-M, Saarela M (2008, June). Optimization of growth medium for clostridia and phylogenetically related bacteria of human GI-tract. *RRI-INRA 2008*.

Mättö J, Saarela M. Susceptibility of bifidobacteria to selected antibiotics as determined by the Etest method. Nutrition and Food Safety: Evaluation of Benefits and Risks (The SAFE Consortium). Budapest, Hungary, 11-14.6.2006.

Mättö J, Maukonen J, Suihko M-L, Alakomi H-L & Saarela M (2007, May). Influence of doxycycline therapy on the diversity and antibiotic susceptibility of human intestinal bifidobacterial population. *107th General Meeting, Toronto, Canada, Abstracts.* American Society for Microbiology. Washington, DC.

Nyström L, Lampi A.-M., Aura A.-M, Oksman-Caldentey K.-M. & Piironen V. 2005. Effects of processing on availability of plant sterols from rye bran. 50 Years ICC - Jubilee Conference 1955-2005 Cereals - The Future Challenge. Vienna, Austria, 3-6 July 2005, 138.

Pimentel LL, Mättö J, Gomes AMP, Pintado MME, Malcata FX, Saarela M. Survival of potentially probiotic enterococci in the GI tract. 4<sup>th</sup> NIZO dairy conference – prospects for health, well-being and safety. Papendal, The Netherlands, June 15-17, 2005.

Saarela M, Maukonen J, Atte von Wright, T. Vilpponen-Salmela, J Mättö. Influence of oral tetracycline therapy on intestinal microbiota and tetracycline susceptibility of the ingested probiotic strains. 8<sup>th</sup> symposium on lactic acid bacteria – genetics, metabolism and applications. Egmond aan Zee, The Netherlands, August 28 to September 1, 2005.

Saarela M, Maukonen J, Suihko M-L, Mättö J. Composition and temporal stability of oral and intestinal microbiota during probiotic ingestion. RRI-INRA 2006: Gut Microbiology: Research to Improve Health, Immune Response and Nutrition. Aberdeen Scotland, 21-23.6.2006 (in journal: Reproduction Nutrition Development, 46, Suppl. 1, S113)

Selinheimo E, Katina K, Aura A.-M, Lehtinen P. & Poutanen K. 2009. Use of xylanases and crosslinking enzymes to improve gluten network properties in whole grain wheat bread. C&E Spring Meeting 2009 - Whole Grain Global Summit. Newcastle upon Tyne, UK, 25-27 March 2009. AACC International. Cereal Foods World. Online Supplement. Vol. 54 (No: 2), OS13.

Maukonen J, Puupponen-Pimiä R & Saarela M. Temporal stability and diversity of human fecal predominant bacterial population during berry intervention. ASM Conferences Beneficial Microbes. San Diego, CA, USA, 12 - 16 Oct. 2008. American Society for Microbiology ( 2008), 24.

Kassinen A, Malinen E, Rinttilä T, Kajander K, Mättö J, Krogius L, Saarela M, Korpela R, Palva, A, Comparison of the faecal microbial populations of patients suffering from irritable bowel syndrome with symptom-free age- and sex-matched controls. Conf. Proc. New Perspectives of Probiotics. Kosice, Slovakia, 15 - 19 Sept. 2004 (2004) , 73.

Mättö J & Saarela M. Composition and stability of bifidobacterial population in irritable bowel syndrome and control subjects. Int. Symp. Propionibacteria and Bifidobacteria. StMalo, France, 2 - 4 June 2004 (2004).

Mättö J, Maunuksela L & Saarela M. Composition and stability of faecal microbiota in irritable bowel syndrome as compared to healthy controls. VTT Symposium 226. The Food, GI-tract Functionality and Human Health Cluster. PROEUHEALTH. Abstracts and posters. Taormina, IT, 3 - 5 March 2003. Kuokka, Annemari, Saarela, Maria & Mattila-Sandholm, Tiina (eds.). VTT Biotechnology. Espoo (2003), 56.

Mättö J & Saarela, M. Composition of bifidobacterial population in irritable bowel syndrome and control subjects. VTT Symposium 232. The Food, GI-tract Functionality and Human Health Cluster. PROEUHEALTH. Abstracts and posters. 3rd Workshop. Sitges, Spain, 15 - 17 March 2004. Ahonen, R., Saarela, M. & Mattila-Sandholm, T. (Eds). VTT Biotechnology. Espoo (2004) , 83.

Mättö J, Wright, A von, Fonden R, Vilpponen-Salmela T, Satokari R & Saarela M. Human colonisation studies with a product containing three different probiotics. VTT Symposium 198. Functional Foods for EU Health in 2000. 4th Workshop FAIR CT 96-1028, PROBDEMO, Rovaniemi, FI, 25 - 28 Feb. 2000. VTT Biotechnology. Espoo (2000), 85.

Saarela M. Influence of oral tetracycline therapy on intestinal microbiota and tetracycline susceptibility of the ingested probiotic strains. 7th European Congress of Chemotherapy and Infection. Florence, Italy, 19 - 22 Oct. 2005 (2005).

Palva A, Malinen E, Mättö J, Salmitie M, Alander M & Saarela M. PCR-ELISA for analysis of bifidobacterial population in human faecal samples from a feeding trial with probiotic *Bifidobacterium lactis* Bb-12 strain and/or prebiotic Elix'or preparation. Proc. Probiotics & Prebiotics. Rome 2 - 4 Sept. 2001 (2001), 238.

Pimentel L.L. Mättö J, Gomes A.M.P. Pintado M.M.E. Malcata F.X. & Saarela M. Survival of potentially probiotic enterococci in the GI tract. 4th NIZO Dairy Conference Prospects for Health, Well-being and Safety. Papendal, The Netherlands, 15 - 17 June 2005 (2005).

Karjalainen S. Söderling E. Lille M, Nohynek L, Autio K, Saarela M. The effect of liquorice extract-containing starch gel on the amount and microbial composition of plaque. 51st ORCA Congr. Marburg, Germany, 30 June - 3 July 2004. Caries Research (2004) No: 38, 359.

Bennet R. Nord C.-E & Mättö J. Faecal recovery and absence of side effects in children given *Lactobacillus* F19 or placebo. VTT Symposium 198. Functional Foods for EU Health in 2000. 4th Workshop FAIR CT 96-1028, PROBDEMO, Rovaniemi, FI, 25 - 28 Feb. 2000. VTT Biotechnology. Espoo (2000), 72 – 73.

Mättö J, Alander M, Johansson M & Crittenden R. Feeding trial with galacto-oligosaccharide and/or *Bifidobacterium lactis* strain Bb-12. VTT Symposium 198. Functional Foods for EU Health in 2000. 4th Workshop FAIR CT 96-1028, PROBDEMO, Rovaniemi, FI, 25 - 28 Feb. 2000. VTT Biotechnology. Espoo (2000), 81 – 82.

## Presentations

Aura A.-M. 2003. Dietary fibre, phenolic compounds and colon health. Joint symp. Lipid and Cereal Sciences in Europe. Vichy, France, 15-17 Nov. 2003.

Aura A.-M, Heinonen S.-M, Adlercreutz H, Karppinen S, Oksman-Caldentey K.-M. & Poutanen K. 2003. Different seed matrices of rye and flax affect the bioavailability of enterolactone precursors. Phytochemistry and Biology of Lignans. Bornheim-Walberberg, 6-9 April 2003.

Aura A.-M, Myllymäki O, Bailey M, Peñalvo J.-L, Adlercreutz H. & Poutanen K. 2006. Effect of carbohydrate type on *in vitro* conversion of enterolactone from rye lignans. Dietary Fibre. Multifunctional Complex of Components. Helsinki, Finland, 12-14 June 2006.

Aura A.-M, Seppänen-Laakso T, Mattila I, Guyot S, Renard C.M.G.C, Souquet J.-M, Cheynier V. & Oksman-Caldentey K.-M. 2006. Microbial metabolism of (+)-catechin, (-)-epicatechin and proanthocyanidins by human fecal microbiota *in vitro*. XXIII International Conference on Polyphenols. Winnipeg, Canada, 22-25 Aug. 2006.

Aura A.-M, Mattila I, Seppänen-Laakso T, Oresic M. & Oksman-Caldentey K.-M. 2007. Colon, a forgotten site of human xenobiotic metabolism? Plants for Human Health in the Post-Genome Era. PSE Congress. Helsinki, FI, 26-29 Aug. 2007. Kuokka-Ihalainen, A., Oksman-Caldentey, K.-M., Rischer, H. & Ritala, A. (eds). VTT Symposium 249. VTT, Espoo. 22/08.

Maukonen J. Molecular techniques and microscopy in bacterial detection and typing. *Microbial Contaminants & Contamination Routes in Food Industry, Espoo, Finland*. Wirtanen, Gun; Salo, Satu (Eds). VTT Symposium 248. VTT, Espoo 2007, 46 – 50.

Puupponen-Pimiä R, Nohynek L, Aura A.-M, Seppänen-Laakso T, Mattila I. & Oksman-Caldentey K.-M. 2007. Human berry intervention study - microbial metabolites of berry phenolics from faecal samples. Plants for Human Health in the Post-Genome Era. PSE Congress. Helsinki, FI, 26-29 Aug. 2007. Kuokka-Ihalainen, A., Oksman-Caldentey, K.-M., Rischer, H. & Ritala, A. (eds). VTT Symposium 249. VTT, Espoo. 83/B15.

- Saarela M. Intra- and interindividual comparison of *Porphyromonas gingivalis* genotypes. FEMS. Antalya, Turkkki, 1992.
- Saarela M. Characterization of dental pathogens by rRNA gene restriction patterns. DIG-symposium, Helsinki, 1992.
- Saarela M. Serotyping, ribotyping and PCR as tools in studies on transmission of oral pathogens. Helsinki University seminar series, 7.11.1994.
- Saarela M. Bakteritko yksilöitä? Parodontologian osaston koulutuspäivä 31.8.1995. (in Finnish)
- Saarela M. Anaerobic actinomycetes. Helsinki University – actinomycetes symposium. 7.12.1995.
- Saarela M. Suun haittamikrobit ja vaikutukset suoliston mikrobeihin. Tekes GutHealth-seminaari, Espoo, 25.2.2002. (in Finnish)
- Saarela M. European perspective on gut health foods for consumer needs. Vitafoods, Geneve, 14-15.2002
- Saarela M. Is there a connection between mouth and gut microbiota? Flair-Flow, Espoo, Finland, 13.6.2002
- Saarela M. Molecular fingerprinting as an epidemiological tool. SAFE consortium seminar, Brussels, Belgium, 24-25.4.2003
- Saarela M. Success story: EU 5th framework programme: Food, GI tract functionality and human health cluster - experiences and prospects, FEMS congress of European microbiologists, Slovenia, 29.6-3.7.2003.
- Saarela M. The stressful life of microbes, Tekes-seminar - GutHealth market, Helsinki, 16.10.2003
- Saarela M. EU 5<sup>th</sup> framework food, GI-tract functionality and human health cluster – experiences and prospects. Pre- and probiotics workshop, Binzen, Germany, 10-13.2004.
- Saarela M. EU 5<sup>th</sup> framework food, GI-tract functionality and human health cluster – experiences and prospects. Joint meeting between SOMED NO XXVIII and Association for Gnotobiotics XXVIII, Helsingor, Denmark, 6-9.5.2004.
- Saarela M. Influence of oral tetracycline therapy on intestinal microbiota and tetracycline susceptibility of the ingested probiotic strains. 7th European congress of chemotherapy and infection. Florence, Italy, 19-22.10.2005.
- Saarela M. Probiotics and antibiotic therapy. ABS lecture course on Molecular Biology of Intestinal Microbiota, Probiotics and Food Chain Bacteria, Helsinki, Finland, 7-9.6.2006.
- Saarela M. Maintaining probiotic viability and stability throughout production steps and in the gastrointestinal tract. International probiotics Conference IPC2008, High Tatras, Slovakia 4-7.6.2008